MedPath

Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life.

Recruiting
Conditions
Myopia
Registration Number
NCT06912802
Lead Sponsor
Santen SAS
Brief Summary

This study aims to assess the impact of myopia in childhood and its long-term complications in adulthood on health-related Quality of Life (HRQoL), providing valuable data for cost-effectiveness models. It will gather country-specific information on healthcare resource utilization, including treatment costs, access to care, and reimbursement policies. In addition, the study will examine how myopia and its treatments affect daily activities and evaluate treatment satisfaction. No data on the efficacy of myopia treatments is collected in this study, and neither is the occurrence of adverse events.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
350
Inclusion Criteria
  • Parents (or other proxy) of children or adolescents aged 5 years or older suffering from myopia (low, moderate, or high myopia) defined by their spherical equivalent (SER): Low myopia is from -0.5 D (inclusive) to -3.0 D (inclusive), Moderate myopia is from -3.0 D to -6.0 D (inclusive) and High myopia is <-6.0 D.
  • Adults suffering from myopia and its complications such as: cataract, macular degeneration, open-angle glaucoma, retinal detachment, and legal blindness/severe visual impairment.
  • Patients where myopia is a known or likely contributing factor to the complication.
Exclusion Criteria
  • Parents (or other proxy) of children aged 4 years and below.
  • Patients where the complication is likely unrelated to myopia (e.g., cataract caused by diabetes) will be excluded

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Group 1 respondents' assessment of EQ-5D-Y-3L (proxy)Through study completion, an average of 6 months

Group 1 respondents are parents (or other proxy) of children and adolescents suffering from myopia.

The EQ-5D-Y-3L (European Quality of Life 5 Dimensions 3 Level) proxy version is an instrument used to assess health-related quality of life (HRQoL) of children and adolescents from the perspective of a parent, caregiver or another proxy. It uses a three-level scale (no problems, some problems or a lot of problems) along with a visual analogue scale (VAS) from 0 (worst imaginable health) to 100 (best imaginable health). The EQ-5D-Y-3L value sets will be used to calculate utility values.

Group 1 respondents' assessment of Bolt-on visionThrough study completion, an average of 6 months

Group 1 respondents are parents (or other proxy) of children and adolescents suffering from myopia.

The vision bolt-on assessment is an extension to the EQ-5D tool to specifically address the impact of vision impairment on a person's quality of life and consists of a single question in the same format.

Group 1 respondents' assessment of PedEyeQ (Pediatric Eye Questionnaire)Through study completion, an average of 6 months

Group 1 respondents are parents (or other proxy) of children and adolescents suffering from myopia.

The PedEyeQ (Pediatric Eye Questionnaire) proxy version is a HRQoL (Health Related Quality of Life) assessment tool specifically designed to measure the impact of pediatric eye conditions on children. The tool consists of age-appropriate questionnaires (5-11 years old and 12-17 years old) that assess how vision problems affect daily activities, social interactions, school performance, and overall well-being of the child.

Group 2 respondents' assessment of EQ-5D-5LThrough study completion, an average of 6 months

Group 2 respondents are adult patients suffering from myopia and a long-term complication of myopia.

The EQ-5D-5L (European Quality of Life 5 Dimensions 3 Level) includes five questions covering mobility, self-care, usual activities, pain/discomfort and anxiety/depression. This questionnaire will be administered to adults suffering from myopia plus a complication. Each domain is rated from 1 (best quality) to 5 (worst quality), along with a VAS from 0 (worst imaginable health) to 100 (best imaginable health).

Group 2 respondents' assessment of Bolt-on visionThrough study completion, an average of 6 months

Group 2 respondents are adult patients suffering from myopia and a long-term complication of myopia.

The vision bolt-on is an extension to the EQ-5D tool to specifically address the impact of vision impairment on a person's quality of life. The EQ-5D-5L value sets will be used to calculate utility values for adults with myopia and its complications.

Group 2 respondents' assessment of NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire-25)Through study completion, an average of 6 months

Group 2 respondents are adult patients suffering from myopia and a long-term complication of myopia.

The NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire-25) is a tool used to assess VRQoL (Vision Related Quality of Life) in individuals aged 18 and older. It consists of 25 items that measure the impact of vision impairment on daily activities and well-being across 12 domains, including visual function, mental health, social functioning, and role limitations. The NEI-VFQ-25 helps evaluate how visual problems affect a person's ability to perform tasks like reading, driving, and interacting socially.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (10)

Copenhagen University Hospital

🇩🇰

Copenhagen, Denmark

University Hospital Necker Enfants Malades

🇫🇷

Paris, France

Klinik für Augenheilkunde (Universitätsklinikum Freiburg)

🇩🇪

Freiburg, Germany

Universitäts-Augenklinik Mainz

🇩🇪

Mainz, Germany

Meyer Children's Hospital IRCCS

🇮🇹

Florence, Italy

Policlinico Universitario Agostino Gemelli IRCCS

🇮🇹

Rome, Italy

Estudio Oftalmologico

🇪🇸

Madrid, Spain

The San Carlos Clinic Hospital (Hospital Clinico San Carlos-HCSC)

🇪🇸

Madrid, Spain

St. Erik Eye Hospital

🇸🇪

Solna, Sweden

Moorfields Eye Hospital NHS Foundation Trust

🇬🇧

London, United Kingdom

Copenhagen University Hospital
🇩🇰Copenhagen, Denmark
Prof. Kessel
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.